AFT PHARMACEUTICALS

AFT
End-of-day quote. End-of-day quote  - 11/26
4.8NZD +2.13%
Income Statement Evolution
Annual Income Statement Data
Fiscal Period: March 2020 2021
Net sales1 106118
EBITDA1 12,517,4
Operating profit (EBIT)1 11,415,9
Operating Margin 10,8%13,5%
Pre-Tax Profit (EBT)1 12,912,6
Net income1 12,711,7
Net margin 12,0%9,89%
EPS2 0,120,11
Dividend per Share2 --
Last update 05/19/202010/29/2020
1 NZD in Million
2 NZD
Estimates
Finances - Leverage
Fiscal Period: March 2020 2021
Net Debt1 41,126,2
Net Cash position1 --
Leverage (Debt / EBITDA) 3,28x1,51x
Free Cash Flow1 -3,50
ROE (Net Profit / Equities) 114%32,8%
Shareholders' equity1 11,235,6
ROA (Net Profit / Asset) -14,1%
Assets1 -82,7
Book Value Per Share2 0,180,38
Cash Flow per Share2 -0,10
Capex1 6,565,28
Capex / Sales 6,21%4,48%
Last update 05/19/202011/24/2020
1 NZD in Million
2 NZD
Estimates
Balance Sheet Analysis
Financial Ratios
Size 2021e 2022e
Capitalization 502 M NZD -
Entreprise Value (EV) 528 M NZD 521 M NZD
Valuation 2021e 2022e
P/E ratio (Price / EPS) 42,8x 24,1x
Capitalization / Revenue 4,26x 3,57x
EV / Revenue 4,48x 3,76x
EV / EBITDA 30,3x 19,9x
Yield (DPS / Price) - 0,90%
Price to book (Price / BVPS) 12,5x 9,01x
Profitability 2021e 2022e
Operating Margin (EBIT / Sales) 13,5% 18,6%
Operating Leverage (Delta EBIT / Delta Sales) 3,40x 3,32x
Net Margin (Net Profit / Revenue) 9,89% 14,8%
ROA (Net Profit / Asset) 14,1% 22,1%
ROE (Net Profit / Equities) 32,8% 38,5%
Rate of Dividend - 21,6%
Balance Sheet Analysis 2021e 2022e
CAPEX / Sales   4,48% 3,85%
Cash Flow / Sales 9,25% 12,7%
Capital Intensity (Assets / Sales) 0,70x 0,67x
Financial Leverage (Net Debt / EBITDA) 1,51x 0,70x
Price Earning Ratio
EPS & Dividend